(HealthDay)—Screening for breast and ovarian cancer genes might be added to the list of medical tests that can be safely and effectively done from home, new research suggests.
Jun 3, 2020
0
4
(HealthDay) -- Due to the potential survival and treatment response implications of BRCA mutation status, it is recommended that germ-line BRCA1/2 testing be offered to all women diagnosed with nonmucinous ovarian carcinoma, ...
Jun 19, 2012
0
0
A report from St. Jude Children's Research Hospital links inherited mutations in the BRCA2 gene with an increased risk of developing non-Hodgkin lymphoma in children and adolescents. The work appears as an advance online ...
Jul 25, 2019
0
0
Rates of genetic testing for BRCA1 and BRCA2 mutations have increased among women diagnosed with breast cancer at age 40 or younger, according to an article published online by JAMA Oncology.
Feb 11, 2016
0
34
Scientists have found that a specific type of ovarian cancer could possibly benefit from existing platinum-based chemotherapy and new DNA repairing treatments, following better testing.
Jun 8, 2020
0
7
It is estimated that between 5% and 10% of breast and ovarian cancers are familial in origin, which is to say that these tumours are attributable to inherited mutations from the parents in genes such as BRCA1 or BRCA2. In ...
Jun 18, 2013
0
0
Olaparib, an experimental twice-daily oral cancer drug, produces an overall tumor response rate of 26 percent in several advanced cancers associated with BRCA1 and BRCA2 mutations, according to new research co-led by the ...
Nov 6, 2014
0
0
Patients with breast cancer who had a BRCA1 mutation had significantly worse overall and recurrence-free survival rates compared with patients without BRCA mutations, but no evidence for a difference in survival was found ...
Apr 9, 2013
0
0
(HealthDay)—A leading U.S. government panel has recommended against ovarian cancer screening for women who are not at high risk for the disease.
Sep 10, 2012
0
0
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced ...
May 15, 2013
0
1
